Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SNC116 in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
NCT07830238Phase 1Not yet recruiting
- Sponsor
- Simnova Biotherapeutics
- Start
- Sep 2026
- Primary completion
- Mar 2030
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SNC116 in acute lymphoblastic leukemia (ALL), sponsored by Simnova Biotherapeutics. Primary endpoints: Adverse Events at 3 months and Dose-Limiting Toxicity at 28 days. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
SNC116
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT07830238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07830238.